Cedric Hermans: The Next Generation of FVIIIa-Mimetic Antibodies in Haemophilia A
Cedric Hermans, Co-Chair FVIII/FIX SSC ISTH 2025, shared a post on LinkedIn about recent article he and his colleauges co-authored, published in Blood Reviews, adding:
“It is a great pleasure to share our review, published online today in Blood Reviews:
‘Exploring the evolving landscape of bispecific FVIIIa-mimetic antibodies in haemophilia A’
FVIIIa-mimetic antibodies have transformed haemophilia A care—and the lives of people living with the condition.
Beginning with emicizumab, this therapeutic approach has brought subcutaneous prophylaxis to people with and without FVIII inhibitors, offering protection from bleeding, reducing treatment burden and supporting a more active life.
As the field continues to evolve, our review explores:
- The extensive clinical trial and real-world evidence for emicizumab across all life stages.
- The next generation of bispecific FVIIIa-mimetic antibodies in advanced clinical development.
- Their molecular designs, dosing regimens and distinct preclinical and clinical profiles.
A comprehensive overview for colleagues seeking to understand both the achievements and the future potential of this rapidly evolving therapeutic class.
Many thanks to all my co-authors for this collaboration.
Read the review.”
Title: Exploring the evolving landscape of bispecific FVIIIa-mimetic antibodies in haemophilia A
Authors: Cedric Hermans, Janice M. Staber, Priyanka Raheja, Michaela Lehle, Anna Kiialainen, Christophe Schmitt, Dan Hart, Matthew Locke, Davide Matino, Yesim Dargaud
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 17:43Santagata Davide: Can Targeting Inflammation Help Prevent Thrombosis?
-
Oct 30, 2026, 17:38Patrick Ellsworth: Supporting Patients and Families Through Bleeding Disorders Awareness and Community Initiatives
-
Oct 30, 2026, 17:33Ed Shovelin: Comparative Hemostatic Performance of CRP-A and Equine Fibrillar Collagen
-
Oct 30, 2026, 16:52Tosin Ola: A New Era in Sickle Cell Disease Treatment and the Question of Access
-
Oct 30, 2026, 16:44Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management
-
Oct 30, 2026, 16:01Marilena Vrana: The Case for Retaining Immunoglobulins on the EU Critical Medicines List